C hronic kidney disease (CKD) afflicts approximately 11% of the general worldwide population, and represents an important global health challenge. 1 CKD evolves over many years, with progressive loss of renal function, which could eventually lead to renal replacement therapy (dialysis) and kidney transplantation. Over the course of the disease, there is a progressive increase in both mortality and comorbidities, primarily due to the development of cardiovascular disease (CVD). 2 Consequently, early therapeutic intervention is essential to slow CKD progression, prevent end-stage renal disease, and improve the quality of life and longevity of patients.
CKD is characterized by heightened levels of oxidative stress, advanced glycation end-products, proinflammatory cytokines, and uremic toxins. 3 Pathogenic signaling initiated by these factors induces changes in epigenetic marks, including methylation and acetylation on chromatin-associated proteins. 4, 5 BET proteins BRD2, BRD3, BRD4, and BRDT are epigenetic readers that use small interaction modules called bromodomains (BDs) to bind to acetylated lysineÀtagged histones and transcription factors associated with transcriptionally active chromatin. [6] [7] [8] Binding leads to the recruitment of the transcriptional machinery that drives gene expression. [9] [10] [11] [12] [13] In disease states, abnormal signaling often results in overabundant or mislocalized acetylation marks, overexpression of BET proteins, and increased BET protein occupancy of gene regulatory regions. [14] [15] [16] [17] [18] [19] [20] [21] This causes changes to gene transcription patterns that control cell fate, proliferation and activation in cancer, fibrosis, autoimmunity, and inflammation. [14] [15] [16] [17] [18] [19] [20] [21] Recently, BET proteins were shown to contribute to renal disorders, including experimental polycystic kidney disease and renal inflammatory disease. [22] [23] [24] [25] [26] Importantly, in these studies, small molecule inhibitors targeting the BDs of BET proteins countered aberrant gene transcription, which led to improved renal outcomes. [22] [23] [24] 26 Apabetalone (RVX-208) is a first-in-class orally available BET inhibitor (BETi) developed to treat CVD. [27] [28] [29] [30] [31] [32] In biochemical assays, apabetalone targeted the second BD (BD2) of BET proteins with 20-to 30-fold selectivity. 33, 34 In cells, BD2 binding by apabetalone resulted in differential transcriptional effects compared with a pan-BETi that targeted both BD1 and BD2 with equal affinity. 34, 35 Apabetalone downregulated immune, inflammatory, and proatherosclerotic genes in ex vivoÀtreated human blood cells and primary hepatocytes, as well as in a mouse model of atherosclerosis. 30, [36] [37] [38] Furthermore, apabetalone improved the plasma lipid profiles of CVD patients and significantly lowered the incidence of major adverse cardiac events in the Study of Quantitative Serial Trends in Lipids with Apolipoprotein A-I Stimulation (SUSTAIN) and the ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation (ASSURE) phase 2 trials. 30, 39 Although highpotency pan-BETi are currently being tested for cancer indications, 40 apabetalone was the first BETi to enter clinical trials for the treatment of CVD. Determining the scope of the in vivo actions of apabetalone is currently an area of active investigation. [27] [28] [29] [30] [31] CKD is characterized by a strong immune and inflammatory component that contributes to accelerated endothelial dysfunction, vascular inflammation, atherosclerosis, and calcification. 41, 42 CKD patients often succumb to cardiovascular complications because current therapies fail to treat the key pathogenic mechanisms underlying disease progression. 43 To evaluate the potential of apabetalone as a CKD therapeutic, we examined the pharmacokinetics of apabetalone in a phase 1, open-label, parallel group study of patients with an estimated glomerular rate (eGFR) of <30 ml/min per 1.73 m 2 . Using a novel aptamer-based proteomics approach coupled to bioinformatics, we identified proteins enriched in the plasma from patients with impaired kidney function, relative to control subjects. Furthermore, we demonstrated that a single dose of apabetalone downregulated plasma markers of endothelial dysfunction, atherosclerosis, vascular inflammation, calcification, fibrosis, hemostasis, and chronic inflammation, countering the pathogenic signaling in CKD patients.
These findings suggest that apabetalone treatment might benefit CKD patients.
METHODS

Patient Selection
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study. The phase I apabetalone pharmacokinetic study consisted of 2 cohorts of 8 subjects each who received a single 100-mg oral dose of apabetalone after a meal. Cohort 1 consisted of subjects with stage 4 or 5 CKD who were not on dialysis, with an eGFR of <30 ml/min per 1.73 m 2 and a mean eGFR of 20 ml/min per 1.73 m 2 . Cohort 2 consisted of control subjects matched to the renally impaired subjects in age, weight, and sex, as well as an eGFR of $60 ml/min per 1.73 m 2 , with mean eGFR of 78.5 ml/min per 1.73 m 2 . Additional characteristics of the cohorts are provided in Table 1 .
Apabetalone Pharmacokinetics and Safety
Blood samples for determination of plasma concentration of apabetalone were collected at the following time 
SOMAscan Analysis
Patient plasma samples collected at baseline and at 6, 12, 24, 48 hours after the single apabetalone dose underwent proteomic analysis using the SOMAscan 1.3k platform (SomaLogic, Boulder, Colorado). 44 SOMAscan uses modified aptamers to simultaneously detect 1305 proteins. The assay can quantify proteins that span over 8 logs in abundance (from femtomolar to micromolar), which allows direct analysis of plasma samples without depletion of abundant proteins. The SOMAscan assay transforms protein concentrations into DNA aptamer concentrations that are quantifiable on a DNA microarray. Changes in relative fluorescent units, which are directly proportional to the amount of target protein in the initial sample, were expressed relative to baseline. 44 
Statistical Analysis
To assess the differential protein levels at baseline between cohort 1 and cohort 2, the Mann-Whitney test was used when data were not normally distributed; otherwise Student's t-tests were used. The BenjaminiHochberg false discovery rate (FDR) multiple testing correction was used to generate FDR-adjusted P values. An adjusted P value < 0.05 was considered significant. Shapiro-Wilk tests were used to determine data distribution.
Changes in protein levels were compared from baseline to 12 hours post-apabetalone dose in all patients. For normally distributed protein parameters, paired Student's t-tests were used to examine the change in protein levels, whereas the Wilcoxon signed-rank test was applied for non-normally distributed parameters. A P value < 0.05 was considered significant. ShapiroWilk tests were used to determine data distribution.
Pathway Analysis QIAGEN's Ingenuity Pathway Analysis software (IPA; QIAGEN, Redwood City, California; www.qiagen.com/ ingenuity) was used to interpret the proteomics data.
RESULTS
Pharmacokinetics of Apabetalone in Control and Stage 4 or 5 CKD Patients
In this study, we compared 8 subjects with eGFRs ranging from 9 to 29 ml/min per 1.73 m 2 (cohort 1, CKD stage 4 or 5, and median creatinine clearance 18.8 ml/min per square meter) and 8 subjects with eGFR ranging from 66 to 109 ml/min per 1.73 m 2 (cohort 2, age-, sex-, weight-matched, and median creatinine clearance 78.4 ml/min per square meter). In addition to stage 4 or 5 CKD, cohort 1 also displayed comorbidities that commonly accompany renal disease, including CVD, diabetes, and hypothyroidism (Table 1) . Baseline plasma samples were obtained from both cohorts to assess clinical biochemistry parameters. Comparison of apabetalone pharmacokinetics following a single dose revealed that the maximum (peak) serum concentration, area under the curve, time to reach maximum (peak) serum concentration (T max ), and terminal halflife were similar for both the renally impaired and matched subjects (Supplementary Table S1 ). Minimal amounts of apabetalone were excreted in the urine of either cohort (Supplementary Table S2 ), which is consistent with the elimination of apabetalone through hepatic clearance. No significant adverse events occurred during the study in the control or the CKD cohorts (data not shown).
Plasma Proteome Profiling in CKD Patients
To gain insight into the molecular mechanisms that underlie CKD and its comorbidities, the proteomic composition of plasma samples from late-stage CKD (cohort 1) and control (cohort 2) subjects was assessed at baseline with the SOMAscan 1.3k platform ( Figure 1a) . 44 Two hundred eighty-eight proteins were differentially expressed between the 2 cohorts (difference >10%, P < 0.05, FDR <0.2) (Figure 1b and Supplementary Table S3) , forming a database for functional pathway analysis. Upon correction for multiple testing, 167 proteins remained significantly upregulated, whereas 2 proteins were downregulated in the CKD cohort (difference >10%, P < 0.005, FDR <0.05) (Figure 1b and Supplementary Table S3 , column F).
CKD progression is accompanied by an overall increase in the plasma concentration of low-molecularweight (LMW; <45 kDa) proteins due to a decline in the filtration capacity of the kidneys. 45, 46 Analysis showed that 173 of the 288 CKD cohort-enriched proteins were LMW proteins. These LMW proteins showed a greater fold enrichment in the CKD cohort compared with proteins of >45 kDa (2.3 AE 1. Table S3 and references therein). Numerous uremic toxins, as classified by the European Toxin Work Group, 45 were also upregulated in the CKD cohort (Supplementary  Table S4 ). Other enriched proteins included cytokines and their soluble receptors, adhesion molecules, metalloproteases, and complement and coagulation proteins, as well as factors involved in calcification, metabolism, and oxidative stress (Supplementary Table S3 ).
Gene ontology analysis 48 of the CKD cohortÀassociated proteins (FDR <0.2) showed significant enrichment of 53 terms in the molecular function category (Supplementary Table S5 ). The top 21 enriched terms (Table 2) were related to ligand-receptor signaling, with 9 linked to cytokine and chemokine pathways. IPA, 49 with its manually curated database from peer-reviewed literature, further predicted not only the impact of disease on cellular functions (P values), but also the direction of change by calculating the activation z-score (Supplementary Table S6 ). Analysis showed that 234 "disease or function" annotations were increased in the CKD cohort (z score >2), whereas 6 annotations were decreased (z score <À2). In particular, top pathways (Table 3 ) which referred to immune and inflammatory cell migration, proliferation, differentiation, activation, and viability, were all upregulated in plasma from the CKD cohort compared with the control cohort. The IPA analysis also predicted a marked upregulation of 42 canonical pathways (z score >2) and a downregulation of . Note that p values tend to be highly significant for highly enriched proteins. Fold enrichment as a function of protein molecular weight (c). Note that the majority of enriched proteins have a molecular weight of <45 kDa. Protein enrichment also tends to be greater for proteins with molecular weight <45 kDa. Figure S1) . Recovery of LAG3 plasma expression was observed following drug clearance (Supplementary Figure S1) . Therefore, the impact of apabetalone on plasma protein levels in the CKD cohort was analyzed 12 hours postdose (Table 5) .
Numerous plasma proteins with physiological functions relevant for CKD and CVD were downregulated by apabetalone in the CKD cohort. Circulating proatherogenic, inflammatory cytokines interleukin (IL)-6, IL-1, IL-17, IL-12, and IL-23, as well as the IL-15 receptor subunit a, decreased in abundance with apabetalone treatment (10%À29%) ( Table 5 ). Apabetalone reduced levels of metalloproteases (MMP-3, MMP-10) and extracellular matrix proteins (fibronectin, osteopontin) (11%À25%). Markers of fibrinolysis were also downregulated, including plasminogen activator inhibitor-1, tissue-type plasminogen activator, and urokinase-like plasminogen activator (42%, 28% and 18%, respectively), as well as a marker of platelet activation and vascular inflammation, P-selectin (23%). Furthermore, apabetalone decreased the abundance of activated fragments of complement proteins, including anaphylatoxin C5a (12%) ( Table 5 ). In contrast, apabetalone had limited effects on disease biomarkers in the control cohort (Table 5) .
To gain insight into the functional effects of apabetalone, the impact of apabetalone on the IPA canonical pathways upregulated in plasma from the CKD cohort was assessed (Table 4) . Remarkably, apabetalone reversed the activation of 33 of 42 pathways in the CKD cohort, with the greatest impact on pathways that were most upregulated in the CKD patients (Table 4) . These canonical pathways regulate inflammation through cytokine signaling, acute phase response, T-cell, and dendritic cell responses. Further, apabetalone downregulated other pathways relevant to CKD pathophysiology: vascular calcification (bone morphogenetic protein signaling), fibrosis (integrin-linked protein kinase signaling), apoptosis (death cell receptor signaling), angiogenesis (vascular endothelial growth factor and pigment epitheliumderived factor signaling), nitric oxide, and reactive oxygen species signaling. Moreover, intracellular signaling pathways converging on the transcription factor nuclear factor-kB (NF-kB) were also downregulated by apabetalone, whereas the peroxisome proliferator-activated receptor pathway was upregulated, countering pathogenic signaling in CKD. 50, 51 Finally, pathways that contribute to comorbidities, such as hypertension, diabetes, and cardiac hypertrophy, were also downregulated by apabetalone (Table 4) . Overall, apabetalone simultaneously modulated multiple pathways that contribute to CKD pathology and associated vascular complications.
DISCUSSION
Changes in plasma protein composition are a central feature of CKD pathophysiology and its associated comorbidities. Until recently, however, attempts to study the plasma proteome have been hampered by the complexity of the plasma protein composition and inherent limitations of mass spectrometry. [52] [53] [54] SOMAscan is a powerful protein discovery tool that Results expressed as median percent change from baseline. c P value comparing change vs. baseline calculated using the Wilcoxon signed-rank test. 44 Here, a total of 169 proteins (adjusted P < 0.05) were identified as differentially expressed in plasma from control and renally impaired cohorts. Approximately 60% were LMW proteins (<45 kDa), consistent with the impairment of kidney filtration in late stage CKD. 45, 46 The plasma proteome presented here shows little overlap with previously published mass spectrometry driven studies (Supplementary Table S3 , column J). [52] [53] [54] In contrast, our data largely corroborates the results of a previous SOMAscan study, 44 in which a smaller panel (614 aptamers) was used to assess stages 3 to 5 CKD patient plasma composition. Forty-five of the 60 markers identified by Gold et al., 44 were also detected in this study (Supplementary Table S3 , column J). Differences may be due to cohort size and composition. Many of the enriched proteins are well established CKD biomarkers that correlate with kidney function and CKD or CVD outcomes (Supplementary Table S3 , columns H and I). These proteins play a role in inflammation, vascular calcification, thrombosis, cell adhesion, extracellular matrix remodeling, oxidative stress, and metabolism. Interestingly, several of the enriched proteins we identified have not been previously linked to CKD or CVD. Establishing the functional relevance of these novel CKD cohort-enriched proteins and determining their prognostic value presents exciting avenues for future studies.
TRANSLATIONAL RESEARCH
Analysis of plasma from renally impaired patients revealed that a single dose of apabetalone rapidly downregulated multiple CKD and CVD protein markers (Table 5) , as well as associated molecular pathways (Table 4 ). In contrast, in the control cohort, apabetalone had no significant effect on pathway activation or repression (as determined by the IPA z-score; data not shown), or on the abundance of most circulating disease markers (Table 5 ). This differential sensitivity to a BET protein inhibitor highlights the dysregulation of BET protein-dependent pathways in human CKD, which is consistent with published data from cell and animal models. 21, 23, 26 Inflammation contributes to the onset and progression of renal disease. 41 Indeed, 40% of the 288 proteins upregulated in the CKD cohort are directly or indirectly linked to inflammation (Supplementary Table S3 ). The most prevalent among these are cytokines and chemokines known to be dysregulated in CKD and its comorbodities. 55 In plasma from the CKD cohort, there was an increase in circulating cytokines (Supplementary Table S3 ), and pathways controlled by IL-6, IL-17, oncostatin M, IL-22, IL-8, and granulocytemacrophage, colony-stimulating factor were predicted to be activated (Table 4) . Significantly, a single dose of apabetalone reduced the plasma protein levels of multiple cytokines and chemokines, including IL-6, IL-12, IL-17, and IL-23 (Table 5 ). In addition, apabetalone was predicted to counter the CKD cohortÀassociated upregulation of cytokine pathways, including IL-6, IL-8, and IL-17 (Table 4) . Essential components of the innate and adaptive immune system 56, 57 were among the top upregulated pathways in the CKD cohort, including the dendritic cell maturation and Th1 signaling pathways (Table 4 , and Supplementary Figures S2 and S3) . Extensive cross-talk occurred between these 2 pathways, with activated dendritic cells stimulating inflammatory Th1 lymphocyte responses, which, in turn, promoted dendritic cell maturation. 58 Apabetalone had a significant impact on both pathways (z scores: À4.2 and À3.3, respectively) ( Table 4 , and Supplementary Figures S2 and S3) , which was consistent with published data. 30, 38 Inflammatory cytokines such as IL-6 induce the acute phase response (APR) protein expression and secretion by the liver. 59 Multiple APR proteins were upregulated in plasma from the CKD cohort potentially due to increased IL-6 signaling (as predicted by IPA) (Supplementary Table S3 and Supplementary  Figures S4 and S5 ). APR signaling pathway was ranked the sixth most activated pathway in CKD plasma (Table 4) . APR proteins are markers of disease progression and become highly enriched in the plasma of stage 3 and 4 CKD patients. 53, 54 Interestingly, this enrichment is greater in plasma of patients with CKD than in the plasma of CVD patients, 53 which indicates that inflammation is exacerbated in patients with advanced kidney failure. 41 Of note, the APR pathway was robustly downregulated by apabetalone (z score: À3.46) ( Table 4 and Supplementary Figure S5 ), in line with previously published data. 30, 37, 38 Consistent with the susceptibility of CKD patients to thrombosis and bleeding, 60 the coagulation system pathway was upregulated in plasma from the CKD cohort (Table 4) . Several circulating hemostatic factors were predictive of CVD events. 61, 62 Apabetalone significantly decreased markers of the fibrinolysis pathway (including plasminogen activator inhibitor-1, urokinase-like plasminogen activator, and tissuetype plasminogen activator) (Table 5) , which are associated with disturbances in hemostasis 63 and atherosclerosis 64 in CKD patients. Inflammation and coagulation can activate the complement cascade, propagating and amplifying proinflammatory signaling and damage. 65 In agreement with previous studies, 37 apabetalone reduced the plasma concentration of activated C3 fragments and of the anaphylatoxin C5a, a marker that has been correlated with CVD outcomes. [66] [67] [68] To date, no adverse events related to coagulation nor complement system dysregulation have been observed in clinical trials with apabetalone 37 (and unpublished data). Increased acetylation of gene promoters and transcription factors such as STAT3 and NF-kB have been detected in cultured renal cells and animal models of inflammatory renal disease. 23, [69] [70] [71] These aberrant acetylated lysine residues become the target of BET proteins (e.g., BRD4) that then drive transcription of inflammatory genes. 23, 71 Apabetalone downregulated the abundance of multiple NF-kB target proteins in plasma from the CKD cohort, including IL-6, IL-1a, IL-12, IL-23, MMP-3, and plasminogen activator inhibitor-1 (Table 5) , and decreased the predicted activation of the NF-kB signaling pathway (z-score: À3.5) ( Table 4 and Supplementary Figure S6) . These data corroborate previously reported inhibition of NF-kBÀdependent pathways by BETi. 16, 23 Current therapies fail to counter progressive systemic inflammation, endothelial dysfunction, vascular calcification, fibrosis, and atherosclerosis in patients with CKD. 43 The plasma proteome study reported here demonstrated that apabetalone might oppose many of these pathogenic pathways in patients with CKD (and its accompanying comorbidities) by rapidly downregulating plasma markers associated with these dysfunctions. Considering its favorable pharmacokinetic properties in CKD patients and a well-established safety profile, 29, 32 apabetalone is a potential therapeutic agent capable of modulating molecular pathways associated with risk factors that drive CKD progression and its cardiovascular complications. 
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